Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
CMS and FDA launch RAPID pathway for breakthrough device coverage

CMS and FDA launch RAPID pathway for breakthrough device coverage

Rule Changes

Medicare coverage for FDA-approved breakthrough devices could arrive as fast as two months after authorization, down from roughly a year

April 23rd, 2026: RAPID coverage pathway announced

Overview

For nearly a decade, medical device makers have faced the same bottleneck: the FDA clears a breakthrough device, and then Medicare spends another year or more deciding whether to pay for it. On April 23, 2026, the two agencies jointly announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway — it cuts that timeline to as little as two months. They simultaneously paused the existing Transitional Coverage for Emerging Technologies (TCET) program for new applicants, consolidating all breakthrough-device coverage work under RAPID.

RAPID synchronizes FDA premarket review with Medicare's national coverage decision. Manufacturers agree upfront on what evidence CMS needs. CMS issues a proposed coverage decision the same day FDA clears the device, followed by a 30-day public comment window.

About 40 devices in the FDA's Breakthrough Devices Program qualify today, with roughly 20 more potentially eligible — concentrated in cardiology, neurology, and chronic-care technology. Industry group AdvaMed called the pathway a positive step but warned that without meaningful timelines and accountability built into program management, patients may not see the full benefits.

Why it matters

Medicare beneficiaries with serious heart, neurological, and chronic conditions could access newly approved devices nearly a year earlier than before.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Who Said What? Predict

Key Indicators

~2 months
New time to Medicare coverage
Target interval between FDA market authorization and final national coverage decision under RAPID.
1 year+
Current time to coverage
Typical delay between FDA clearance and a Medicare national coverage decision under existing process.
~40
Devices eligible now
Breakthrough devices that could qualify for the RAPID pathway immediately, per a senior CMS official.
~20
Additional potential qualifiers
Further devices that could meet RAPID criteria as evidence plans develop.
60 days
Public comment period
Federal Register comment window on the proposed procedural notice before CMS finalizes the pathway.
~250
Cardiology breakthrough devices
Cardiology has the largest share of devices in the FDA Breakthrough Devices Program and stands to benefit most.

Voices

Curated perspectives — historical figures and your fellow readers.

Ayn Rand

Ayn Rand

(1905-1982) · Cold War · philosophy

Fictional AI pastiche — not real quote.

"At last, the bureaucratic hydra consents to trim one of its own heads — not out of principle, but because the absurdity of rewarding innovation with a year of administrative purgatory had become too embarrassing even for Washington. I will celebrate this rationality when it is permanent, and not merely a temporary mercy extended to the productive by those who have never created a thing themselves."

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Marty Makary
Marty Makary
Co-announcing RAPID pathway
 Dr. Mehmet Oz
Dr. Mehmet Oz
Co-announcing RAPID pathway

Organizations Involved

Centers for Medicare & Medicaid Services
Centers for Medicare & Medicaid Services
Federal Agency
Issuing proposed procedural notice; TCET pathway paused for new candidates

The federal agency that decides what Medicare pays for and at what rate.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal Agency
Co-issuing RAPID pathway

The federal agency that reviews medical devices for safety and effectiveness before market authorization.
AdvaMed
AdvaMed
Industry Trade Association
Supporting pathway, lobbying for broader coverage

The largest U.S. trade association representing medical device manufacturers.

Timeline

December 2016 April 2026

8 events Latest: April 23rd, 2026 · 1 month ago
Tap a bar to jump to that date

  1. RAPID coverage pathway announced

    Latest Regulation

    CMS and FDA jointly announce the Regulatory Alignment for Predictable and Immediate Device pathway, targeting Medicare coverage as fast as two months after FDA clearance.

  2. CMS pauses TCET pathway for new candidates

    Regulation

    Alongside the RAPID launch, CMS announced it is pausing the Transitional Coverage for Emerging Technologies program for new applicants, directing breakthrough-device coverage resources entirely toward RAPID implementation.

  3. CMS proposes payment rollback for breakthrough devices

    Regulation

    CMS proposes eliminating the alternate new technology add-on payment pathway that lets breakthrough devices skip the substantial-clinical-improvement test.

  4. TCET pathway finalized

    Regulation

    CMS finalizes TCET, targeting a six-month national coverage decision after FDA authorization, capped at roughly five devices per year.

  5. TCET pathway proposed

    Regulation

    CMS publishes proposed Transitional Coverage for Emerging Technologies pathway, a narrower successor to MCIT.

  6. Biden CMS rescinds MCIT

    Regulation

    CMS repeals the MCIT rule, citing insufficient patient safeguards and weak incentives for post-market evidence development.

  7. MCIT rule finalized

    Regulation

    Outgoing Trump administration finalizes Medicare Coverage of Innovative Technology rule granting four years of automatic Medicare coverage to FDA breakthrough devices.

  8. 21st Century Cures Act signed into law

    Legislation

    Creates the FDA Breakthrough Devices designation, giving priority review to devices that treat serious conditions with unmet medical need.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

January–November 2021

MCIT rule and rescission (2021)

In its final days, the first Trump administration finalized the Medicare Coverage of Innovative Technology rule, giving FDA breakthrough devices four years of automatic Medicare coverage starting at market authorization. The Biden CMS delayed implementation, then formally repealed the rule in November 2021, arguing the four-year window cut off the agency's ability to demand evidence on how devices performed in older, sicker Medicare patients.

Then

Device makers lost automatic coverage; the coverage gap reverted to roughly a year or longer. AdvaMed launched a multi-year lobbying push for a replacement.

Now

The rescission established that tying Medicare coverage directly to FDA approval raised unresolved evidence-standard questions, forcing successor programs to build in pre-market evidence negotiation rather than post-market automatic coverage.

Why this matters now

RAPID is the third attempt to bridge the FDA-to-Medicare gap. It borrows MCIT's speed ambition but answers the 2021 critique by requiring Medicare-specific trial enrollment and agreed outcomes before approval — not coverage first, evidence later.

August 2024

TCET pathway finalized (2024)

The Biden CMS finalized the Transitional Coverage for Emerging Technologies pathway, targeting a six-month national coverage decision after FDA breakthrough device authorization. The program accepted up to five devices per year, required coverage with evidence development, and was intended as a modest, defensible successor to MCIT.

Then

Industry groups welcomed TCET as better than nothing but criticized the five-device cap as far too narrow given the pipeline.

Now

TCET set the procedural template — concurrent review, upfront evidence planning — that RAPID scales up. RAPID removes the five-device cap, cuts the timeline further, and broadens eligibility to include Class II devices in FDA's TAP program.

Why this matters now

RAPID is essentially TCET with the throttle removed. Whether the faster timeline survives public comment intact will hinge on whether the evidence safeguards carried over from TCET persuade skeptics.

July 2012

FDA Breakthrough Therapy designation for drugs (2012)

Congress created the Breakthrough Therapy designation under FDASIA, letting FDA work closely with drug sponsors from early development to speed approval of therapies for serious conditions. Unlike devices, drugs face a separate Medicare coverage mechanism (Part B/D) that does not require national coverage determinations for most products, so approval and reimbursement historically ran in closer sequence.

Then

Dozens of cancer, rare disease, and infectious disease drugs reached patients one to two years earlier than traditional review would have allowed.

Now

The designation normalized the idea that regulators can engineer closer collaboration with sponsors on evidence design without abandoning safety and efficacy standards — the template RAPID now extends to devices plus payers.

Why this matters now

Drugs have had an accelerated front door for more than a decade; devices never bridged the coverage gap that separates approval from reimbursement. RAPID is the structural import of that drug-side playbook into the device and Medicare coverage world.

Sources

(16)
+10
FDA STAT Healthcare Dive MedTech Dive Fierce Healthcare AdvaMed CMS Cardiovascular Business Modern Healthcare Foley Hoag LLP RAPS Discoveries in Health Policy Inside Health Policy Medical Design and Outsourcing CMS STAT